ArticleFrontiers in global women's health2026
Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study.
Article in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dyslipidemia is a prevalent metabolic disorder in breast cancer patients and an important comorbidity that impacts cardiovascular outcomes, treatment tolerance, and long-term prognosis. It may also be linked to tumor progression, yet the distribution characteristics of lipid abnormalities, especially their heterogeneity across different clinical stages and molecular subtypes of breast cancer, remain insufficiently characterized in existing research. Methods: This retrospective observational study was conducted at the Affiliated Zhongshan Hospital of Dalian University, enrolling 5,246 patients with pathologically confirmed primary breast cancer diagnosed from 2014 to 2024 with complete clinical staging and fasting lipid profile data. Dyslipidemia was defined as at least one abnormal lipid parameter (LDL-C ≥ 3.4 mmol/L, HDL-C < 1.0 mmol/L, TC ≥ 5.2 mmol/L, TG ≥ 1.7 mmol/L). Stage-stratified multivariable logistic regression analyses were used to identify independent associated factors, with subtype-based subgroup analyses and sensitivity analyses excluding CHD patients performed to verify result robustness. Results: Dyslipidemia affected 54.8%-71.9% of patients across all clinical stages, with TC and TG abnormalities being the most common, followed by reduced HDL-C and elevated LDL-C. Cumulative proportions of individual lipid abnormalities exceeded 100% per stage, indicating frequent coexistence of multiple abnormalities. Obvious subtype heterogeneity was observed: Luminal B (HER-) had low early-stage HDL-C reduction, while triple-negative patients had a markedly high LDL-C elevation rate (up to 50%) in stage IV. Tumor burden-related factors and selected molecular pathology indicators were independently associated with dyslipidemia in a stage-specific manner, and CHD exclusion did not alter the results. Conclusions: Dyslipidemia is a pervasive and heterogeneous metabolic comorbidity in breast cancer, with distinct stage- and subtype-specific patterns closely linked to tumor burden and molecular biological characteristics. Routine lipid assessment and subtype-tailored metabolic management should be integrated as an essential component into the comprehensive clinical care of breast cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.